231 related articles for article (PubMed ID: 22622825)
21. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
[TBL] [Abstract][Full Text] [Related]
22. Hesperidin protects against behavioral alterations and loss of dopaminergic neurons in 6-OHDA-lesioned mice: the role of mitochondrial dysfunction and apoptosis.
Antunes MS; Ladd FVL; Ladd AABL; Moreira AL; Boeira SP; Cattelan Souza L
Metab Brain Dis; 2021 Jan; 36(1):153-167. PubMed ID: 33057922
[TBL] [Abstract][Full Text] [Related]
23. Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice.
Antunes MS; Cattelan Souza L; Ladd FVL; Ladd AABL; Moreira AL; Bortolotto VC; Silva MRP; Araújo SM; Prigol M; Nogueira CW; Boeira SP
Mol Neurobiol; 2020 Jul; 57(7):3027-3041. PubMed ID: 32458386
[TBL] [Abstract][Full Text] [Related]
24. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model.
Ren X; Zhang T; Gong X; Hu G; Ding W; Wang X
Exp Neurol; 2013 Oct; 248():148-56. PubMed ID: 23764500
[TBL] [Abstract][Full Text] [Related]
25. Extracellular Zn
Tamano H; Nishio R; Morioka H; Takeda A
Mol Neurobiol; 2019 Jan; 56(1):435-443. PubMed ID: 29705946
[TBL] [Abstract][Full Text] [Related]
26. Protective mechanism of Syringic acid in an experimental model of Parkinson's disease.
Güzelad Ö; Özkan A; Parlak H; Sinen O; Afşar E; Öğüt E; Yıldırım FB; Bülbül M; Ağar A; Aslan M
Metab Brain Dis; 2021 Jun; 36(5):1003-1014. PubMed ID: 33666819
[TBL] [Abstract][Full Text] [Related]
27. [Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine].
Meng JL; Ma YY; Luo HY; Kong SZ; He YW; Dong BC; Wu SH; He M
Sheng Li Xue Bao; 2008 Jun; 60(3):369-74. PubMed ID: 18560728
[TBL] [Abstract][Full Text] [Related]
28. Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats.
Turnes JM; Bassani TB; Souza LC; Vital MABF
J Pharm Pharmacol; 2018 Aug; 70(8):1059-1068. PubMed ID: 29766510
[TBL] [Abstract][Full Text] [Related]
29. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
[TBL] [Abstract][Full Text] [Related]
30. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Rosenblad C; Kirik D; Devaux B; Moffat B; Phillips HS; Björklund A
Eur J Neurosci; 1999 May; 11(5):1554-66. PubMed ID: 10215908
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model.
Xie L; Hu LF; Teo XQ; Tiong CX; Tazzari V; Sparatore A; Del Soldato P; Dawe GS; Bian JS
PLoS One; 2013; 8(4):e60200. PubMed ID: 23573240
[TBL] [Abstract][Full Text] [Related]
32. Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway.
Xu L; Chen WF; Wong MS
Br J Pharmacol; 2009 Oct; 158(3):738-48. PubMed ID: 19703168
[TBL] [Abstract][Full Text] [Related]
33. Altered nucleolar morphology in substantia nigra dopamine neurons following 6-hydroxydopamine lesion in rats.
Healy-Stoffel M; Ahmad SO; Stanford JA; Levant B
Neurosci Lett; 2013 Jun; 546():26-30. PubMed ID: 23643997
[TBL] [Abstract][Full Text] [Related]
34. Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
Crotty S; Fitzgerald P; Tuohy E; Harris DM; Fisher A; Mandel A; Bolton AE; Sullivan AM; Nolan Y
Eur J Neurosci; 2008 Jan; 27(2):294-300. PubMed ID: 18190522
[TBL] [Abstract][Full Text] [Related]
35. Valproate is protective against 6-OHDA-induced dopaminergic neurodegeneration in rodent midbrain: A potential role of BDNF up-regulation.
Lai CL; Lu CC; Lin HC; Sung YF; Wu YP; Hong JS; Peng GS
J Formos Med Assoc; 2019 Jan; 118(1 Pt 3):420-428. PubMed ID: 30031602
[TBL] [Abstract][Full Text] [Related]
36. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
[TBL] [Abstract][Full Text] [Related]
37. Effects of (-)-sesamin on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and dopaminergic neuronal cells of Parkinson's disease rat models.
Park HJ; Zhao TT; Lee KS; Lee SH; Shin KS; Park KH; Choi HS; Lee MK
Neurochem Int; 2015; 83-84():19-27. PubMed ID: 25747493
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture.
Chan WS; Durairajan SS; Lu JH; Wang Y; Xie LX; Kum WF; Koo I; Yung KK; Li M
Neurochem Int; 2009 Nov; 55(6):414-22. PubMed ID: 19409437
[TBL] [Abstract][Full Text] [Related]
39. Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease.
Khan MM; Raza SS; Javed H; Ahmad A; Khan A; Islam F; Safhi MM; Islam F
Neurotox Res; 2012 Jul; 22(1):1-15. PubMed ID: 22194158
[TBL] [Abstract][Full Text] [Related]
40. Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson's disease.
Chen S; Yu SJ; Li Y; Lecca D; Glotfelty E; Kim HK; Choi HI; Hoffer BJ; Greig NH; Kim DS; Wang Y
Sci Rep; 2018 Jul; 8(1):10722. PubMed ID: 30013201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
